Monte Rosa Therapeutics, Inc.

• Monte Rosa Therapeutics, Inc. Estimates – NASDAQ:GLUE
  TradingView · 23 Oct 2026
• Monte Rosa Therapeutics Stock Price Forecast. Should You Buy GLUE?
  StockInvest.us · 16 Oct 2026
• UBS upgrades Monte Rosa Therapeutics stock to Hold while trials advance
  AD HOC NEWS · 15 Oct 2026
• Monte Rosa Therapeutics (NASDAQ:GLUE) Raised to Hold at UBS Group
  MarketBeat · 14 Oct 2026
• Monte Rosa Therapeutics stock fell 3.89 percent as analysts kept targets high
  ad-hoc-news.de · 07 Oct 2026
• Monte Rosa Therapeutics, Inc. (GLUE) Discusses GFORCE-1 Phase I Results for NEK7 Molecular Glue Degrader MRT-8102 in Cardiovascular Disease Risk - Slideshow (NASDAQ:GLUE) 2026-10-05
  Seeking Alpha · 05 Oct 2026
• Guggenheim Sticks to Its Buy Rating for Monte Rosa Therapeutics (GLUE)
  The Globe and Mail · 03 Oct 2026
• Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win
  Simply Wall Street · 03 Oct 2026
• Why is Monte Rosa Therapeutics stock surging 20% today?
  Investing.com · 01 Oct 2026
• Monte Rosa posts trial data for anti-inflammatory drug (GLUE)
  Seeking Alpha · 01 Oct 2026
• Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 6% - What's Next?
  MarketBeat · 01 Oct 2026
• Monte Rosa Therapeutics, Inc. $GLUE Shares Newly Acquired by Bank of America Corp DE
  MarketBeat · 28 Sep 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →